三生製藥(01530.HK)2020年上半年保持穩健增長 未來3年預計提交10多個新產品上市申請
格隆匯 8 月 17日丨三生製藥(01530.HK)公告，截至2020年6月30日止6個月中期業績，收入同比增加2.0%至26.95億元；毛利同比增加1.5%至人民幣22.17億元。母公司擁有人應占純利同比增加118.6%至7.03億元。EBITDA同比增加70.7%至10.03億元。正常化EBITDA同比增加3.1%至人民幣10.49億元。每股基本盈利0.28元。
三生製藥為中國領先的生物製藥公司。集團作為中國生物製藥行業的先鋒，在研發、生產及營銷生物技術產品方面擁有豐富的經驗。集團的核心產品包括特比澳、益賽普及重組人促紅素("rhEPO")產品益比奧及賽博爾。所有四種產品均為中國內地市場領先的產品。特比澳為當今全球唯一商業化的重組人血小板生成素("rhTPO")產品。
根據IQVIA1，於2020年上半年，按銷售額計，特比澳在中國內地血小板減少症治療市場的份額為72.8%。益賽普為腫瘤壞死因子("TNF")α抑制劑產品，於2020年上半年繼續佔據中國內地TNFα市場主導地位，市場份額為54.5%。憑藉兩種rhEPO產品，近二十年來，集團一直為中國內地rhEPO市場龍頭，於2020年上半年共佔rhEPO市場份額41.2%。集團亦通過內部研究及開發及多項外部戰略合作增加產品而擴大治療領域。
截至2020年6月30日止6個月，集團收入增加主要由於2020年初爆發COVID-19大流行病，對集團產品的銷售增長產生負面影響。
母公司擁有人應占純利增加主要由於截至2019年6月30日止6個月三生國健的員工持股計劃項下的獎勵股份有關的開支的一次性影響。正常化母公司擁有人應占純利界定為期內溢利，但不包括(倘適用)(a)發行2022年債券產生的利息開支；及(b)與公司購股權及股份獎勵有關的開支；(c)與三生國健根據員工持股計劃獎勵股份有關的開支；及(d)與收購進展中的研發項目有關的開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
